Newsroom

Glenmark Pharmaceuticals Announces the Company’s First New Drug Application Submission for RyaltrisTM for Patients with Seasonal Allergic Rhinitis

22 May 2018 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Colesevelam Hydrochloride Tablets, 625 mg

21 May 2018 | Read More

Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the International Investigative Dermatology Meeting

18 May 2018 | Read More

Glenmark announces grant of substitution and successful launch of generic Seretide® Accuhaler® in Denmark

16 May 2018 | Read More

New and Updated Data on Glenmark Pharmaceuticals GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis, Including an Oral Presentation, to be Presented at the International Investigative Dermatology Meeting

10 May 2018 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Topical Solution USP, 0.05%

20 Apr 2018 | Read More

Glenmark receives ANDA approval for Tacrolimus Ointment, 0.1%

18 Apr 2018 | Read More

Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis

17 Apr 2018 | Read More

Glenmark Pharmaceuticals and Helsinn Group enter into an exclusive licensing agreement for launch of AKYNZEO® in India and Nepal

4 Apr 2018 | Read More

Glenmark Pharmaceuticals receives ANDA approval for Clobetasol Propionate Spray, 0.05%

27 Mar 2018 | Read More

Glenmark Pharmaceuticals Presents New Data on Ryaltris™, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis at the AAAAI/WAO Joint Congress

6 Mar 2018 | Read More

Glenmark launches a globally-renowned hair growth formula Nourkrin® Woman in India

28 Feb 2018 | Read More

Glenmark Pharmaceuticals Enters Exclusive Collaboration Agreement with SCD Pharmaceuticals, South Korea, for Ophthalmic Solution Products

22 Feb 2018 | Read More

Glenmark Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting

19 Feb 2018 | Read More

Glenmark’s consolidated revenue at Rs. 22,036.62 Mn for Q3 FY 2017 – 18

9 Feb 2018 | Read More

Glenmark presents Preliminary Biomarker Data on GBR 1302, a HER2xCD3 Bispecific Monoclonal Antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium

25 Jan 2018 | Read More

Glenmark initiates Phase IIb dose range finding study for novel molecule GRC 27864

15 Jan 2018 | Read More

Glenmark launches the biosimilar of Adalimumab in India

4 Jan 2018 | Read More

Library

Profile – Chairman and Managing Director
+
Profile – Chairman and Managing Director
With the idea of creating something unique, Glenn Saldanha took over the reins of the company and helped transform it into a global enterprise worth USD 1.4 billion with offices across 40 countries. Download Profile
Profile – Glenmark Pharmaceuticals
+
Profile – Glenmark Pharmaceuticals
Research-driven, global and integrated pharmaceutical company which is driven to meet unmet medical needs and help pave a new way for a new world. Download Profile

For any media related queries, please email corpcomm@glenmarkpharma.com